nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP24A1—bronchus—esophageal cancer	0.0135	0.13	CbGeAlD
Paricalcitol—CYP24A1—trachea—esophageal cancer	0.0121	0.117	CbGeAlD
Paricalcitol—VDR—neck—esophageal cancer	0.0111	0.107	CbGeAlD
Paricalcitol—UGT1A4—digestive system—esophageal cancer	0.0104	0.101	CbGeAlD
Paricalcitol—CYP24A1—digestive system—esophageal cancer	0.0104	0.101	CbGeAlD
Paricalcitol—CYP24A1—lung—esophageal cancer	0.00871	0.084	CbGeAlD
Paricalcitol—VDR—epithelium—esophageal cancer	0.00755	0.0728	CbGeAlD
Paricalcitol—VDR—bronchus—esophageal cancer	0.00744	0.0717	CbGeAlD
Paricalcitol—VDR—trachea—esophageal cancer	0.00668	0.0644	CbGeAlD
Paricalcitol—VDR—digestive system—esophageal cancer	0.00574	0.0554	CbGeAlD
Paricalcitol—VDR—lung—esophageal cancer	0.0048	0.0463	CbGeAlD
Paricalcitol—VDR—lymph node—esophageal cancer	0.00328	0.0316	CbGeAlD
Paricalcitol—CYP24A1—Biological oxidations—ADH7—esophageal cancer	0.00267	0.0049	CbGpPWpGaD
Paricalcitol—Hyperkalaemia—Cisplatin—esophageal cancer	0.00263	0.00748	CcSEcCtD
Paricalcitol—Wheezing—Cisplatin—esophageal cancer	0.0026	0.0074	CcSEcCtD
Paricalcitol—Body temperature increased—Carboplatin—esophageal cancer	0.00257	0.00732	CcSEcCtD
Paricalcitol—Fungal infection—Capecitabine—esophageal cancer	0.00255	0.00727	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—SLC39A6—esophageal cancer	0.00255	0.00468	CbGpPWpGaD
Paricalcitol—Skin ulcer—Capecitabine—esophageal cancer	0.00253	0.00721	CcSEcCtD
Paricalcitol—Rhinorrhoea—Capecitabine—esophageal cancer	0.00243	0.00693	CcSEcCtD
Paricalcitol—Ageusia—Capecitabine—esophageal cancer	0.00243	0.00693	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—ADH7—esophageal cancer	0.00243	0.00446	CbGpPWpGaD
Paricalcitol—Injection site pain—Capecitabine—esophageal cancer	0.00241	0.00688	CcSEcCtD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00235	0.00431	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TNFRSF10A—esophageal cancer	0.00235	0.00431	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—ADH1B—esophageal cancer	0.00234	0.00429	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—CREBBP—esophageal cancer	0.00233	0.00427	CbGpPWpGaD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00232	0.00425	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—BCL2—esophageal cancer	0.00225	0.00413	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—ABL1—esophageal cancer	0.00225	0.00413	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.00224	0.0041	CbGpPWpGaD
Paricalcitol—Chest discomfort—Capecitabine—esophageal cancer	0.00223	0.00635	CcSEcCtD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00221	0.00406	CbGpPWpGaD
Paricalcitol—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00218	0.00622	CcSEcCtD
Paricalcitol—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00218	0.00622	CcSEcCtD
Paricalcitol—CYP24A1—Biological oxidations—CYP26A1—esophageal cancer	0.00218	0.00399	CbGpPWpGaD
Paricalcitol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00217	0.00618	CcSEcCtD
Paricalcitol—Hypocalcaemia—Capecitabine—esophageal cancer	0.00215	0.00613	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00215	0.00394	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTT1—esophageal cancer	0.00214	0.00393	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—ADH7—esophageal cancer	0.00213	0.00391	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—BBC3—esophageal cancer	0.00209	0.00384	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—BAX—esophageal cancer	0.00206	0.00378	CbGpPWpGaD
Paricalcitol—Bone pain—Capecitabine—esophageal cancer	0.00206	0.00586	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00204	0.00374	CbGpPWpGaD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00203	0.00372	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTO1—esophageal cancer	0.00202	0.00371	CbGpPWpGaD
Paricalcitol—Gait disturbance—Capecitabine—esophageal cancer	0.00202	0.00575	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTO1—esophageal cancer	0.00199	0.00366	CbGpPWpGaD
Paricalcitol—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00198	0.00564	CcSEcCtD
Paricalcitol—Stupor—Methotrexate—esophageal cancer	0.00197	0.0056	CcSEcCtD
Paricalcitol—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00194	0.00553	CcSEcCtD
Paricalcitol—CYP3A4—digestive system—esophageal cancer	0.00192	0.0185	CbGeAlD
Paricalcitol—Depressed level of consciousness—Capecitabine—esophageal cancer	0.0019	0.00542	CcSEcCtD
Paricalcitol—Fungal infection—Methotrexate—esophageal cancer	0.0019	0.00541	CcSEcCtD
Paricalcitol—Colitis—Capecitabine—esophageal cancer	0.00189	0.00539	CcSEcCtD
Paricalcitol—Skin ulcer—Methotrexate—esophageal cancer	0.00189	0.00537	CcSEcCtD
Paricalcitol—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00187	0.00343	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—ADH1B—esophageal cancer	0.00187	0.00343	CbGpPWpGaD
Paricalcitol—Dehydration—Cisplatin—esophageal cancer	0.00181	0.00514	CcSEcCtD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.0018	0.0033	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—esophageal cancer	0.00179	0.00329	CbGpPWpGaD
Paricalcitol—Neoplasm—Capecitabine—esophageal cancer	0.00178	0.00508	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—ABCC2—esophageal cancer	0.00177	0.00324	CbGpPWpGaD
Paricalcitol—Breast disorder—Cisplatin—esophageal cancer	0.00175	0.005	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00175	0.00498	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—CYP26A1—esophageal cancer	0.00174	0.00319	CbGpPWpGaD
Paricalcitol—Nasopharyngitis—Cisplatin—esophageal cancer	0.00174	0.00494	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—SFN—esophageal cancer	0.00173	0.00316	CbGpPWpGaD
Paricalcitol—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00172	0.00315	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00172	0.00315	CbGpPWpGaD
Paricalcitol—Sepsis—Capecitabine—esophageal cancer	0.00171	0.00487	CcSEcCtD
Paricalcitol—CYP24A1—Biological oxidations—ALDH2—esophageal cancer	0.00165	0.00302	CbGpPWpGaD
Paricalcitol—Pancreatitis—Cisplatin—esophageal cancer	0.00165	0.00469	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—NFE2L2—esophageal cancer	0.00164	0.00301	CbGpPWpGaD
Paricalcitol—Swelling—Capecitabine—esophageal cancer	0.00162	0.00462	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—GSTO1—esophageal cancer	0.00162	0.00297	CbGpPWpGaD
Paricalcitol—Gastroenteritis—Capecitabine—esophageal cancer	0.00161	0.0046	CcSEcCtD
Paricalcitol—Abdominal discomfort—Cisplatin—esophageal cancer	0.00161	0.00458	CcSEcCtD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.0016	0.00294	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.00159	0.00293	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—EP300—esophageal cancer	0.00159	0.00291	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.00158	0.00289	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTT1—esophageal cancer	0.00157	0.00288	CbGpPWpGaD
Paricalcitol—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00155	0.00285	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP2A6—esophageal cancer	0.00155	0.00284	CbGpPWpGaD
Paricalcitol—Libido decreased—Capecitabine—esophageal cancer	0.00154	0.0044	CcSEcCtD
Paricalcitol—Thirst—Capecitabine—esophageal cancer	0.0015	0.00428	CcSEcCtD
Paricalcitol—Dermatitis bullous—Capecitabine—esophageal cancer	0.0015	0.00426	CcSEcCtD
Paricalcitol—Arthritis—Capecitabine—esophageal cancer	0.00147	0.00419	CcSEcCtD
Paricalcitol—CYP24A1—Biological oxidations—PTGS1—esophageal cancer	0.00147	0.0027	CbGpPWpGaD
Paricalcitol—Vaginal inflammation—Methotrexate—esophageal cancer	0.00147	0.00418	CcSEcCtD
Paricalcitol—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00146	0.00416	CcSEcCtD
Paricalcitol—Conjunctivitis—Cisplatin—esophageal cancer	0.00145	0.00414	CcSEcCtD
Paricalcitol—Osteoarthritis—Capecitabine—esophageal cancer	0.00143	0.00408	CcSEcCtD
Paricalcitol—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00143	0.00408	CcSEcCtD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00143	0.00262	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—esophageal cancer	0.00142	0.00261	CbGpPWpGaD
Paricalcitol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00142	0.00404	CcSEcCtD
Paricalcitol—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00142	0.00404	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—CYP2A6—esophageal cancer	0.00141	0.00259	CbGpPWpGaD
Paricalcitol—Vaginal infection—Methotrexate—esophageal cancer	0.00139	0.00395	CcSEcCtD
Paricalcitol—Cardiac arrest—Capecitabine—esophageal cancer	0.00136	0.00388	CcSEcCtD
Paricalcitol—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00134	0.00247	CbGpPWpGaD
Paricalcitol—Dehydration—Capecitabine—esophageal cancer	0.00133	0.00379	CcSEcCtD
Paricalcitol—Neoplasm—Methotrexate—esophageal cancer	0.00133	0.00378	CcSEcCtD
Paricalcitol—Urinary tract disorder—Cisplatin—esophageal cancer	0.00133	0.00378	CcSEcCtD
Paricalcitol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00132	0.00376	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—ALDH2—esophageal cancer	0.00132	0.00242	CbGpPWpGaD
Paricalcitol—Urethral disorder—Cisplatin—esophageal cancer	0.00132	0.00375	CcSEcCtD
Paricalcitol—Pulmonary oedema—Methotrexate—esophageal cancer	0.00131	0.00372	CcSEcCtD
Paricalcitol—Breast disorder—Capecitabine—esophageal cancer	0.00129	0.00368	CcSEcCtD
Paricalcitol—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00129	0.00367	CcSEcCtD
Paricalcitol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00128	0.00365	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN2A—esophageal cancer	0.00128	0.00234	CbGpPWpGaD
Paricalcitol—Sepsis—Methotrexate—esophageal cancer	0.00127	0.00363	CcSEcCtD
Paricalcitol—Gastritis—Capecitabine—esophageal cancer	0.00127	0.00361	CcSEcCtD
Paricalcitol—Eye disorder—Cisplatin—esophageal cancer	0.00126	0.00358	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—GSTT1—esophageal cancer	0.00125	0.0023	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP1B1—esophageal cancer	0.00125	0.00229	CbGpPWpGaD
Paricalcitol—Lymphadenopathy—Methotrexate—esophageal cancer	0.00125	0.00356	CcSEcCtD
Paricalcitol—Cardiac disorder—Cisplatin—esophageal cancer	0.00125	0.00355	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—CYP2A6—esophageal cancer	0.00124	0.00227	CbGpPWpGaD
Paricalcitol—Dysphagia—Capecitabine—esophageal cancer	0.00124	0.00352	CcSEcCtD
Paricalcitol—Influenza—Capecitabine—esophageal cancer	0.00124	0.00352	CcSEcCtD
Paricalcitol—Asthma—Capecitabine—esophageal cancer	0.00124	0.00352	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00123	0.00226	CbGpPWpGaD
Paricalcitol—Immune system disorder—Cisplatin—esophageal cancer	0.00121	0.00346	CcSEcCtD
Paricalcitol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00121	0.00345	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00121	0.00221	CbGpPWpGaD
Paricalcitol—Arrhythmia—Cisplatin—esophageal cancer	0.0012	0.00342	CcSEcCtD
Paricalcitol—Alopecia—Cisplatin—esophageal cancer	0.00119	0.00338	CcSEcCtD
Paricalcitol—Abdominal discomfort—Capecitabine—esophageal cancer	0.00119	0.00338	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—PTGS1—esophageal cancer	0.00117	0.00215	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP19A1—esophageal cancer	0.00117	0.00215	CbGpPWpGaD
Paricalcitol—Malnutrition—Cisplatin—esophageal cancer	0.00117	0.00333	CcSEcCtD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00116	0.00213	CbGpPWpGaD
Paricalcitol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00115	0.00327	CcSEcCtD
Paricalcitol—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00113	0.00206	CbGpPWpGaD
Paricalcitol—Muscle spasms—Cisplatin—esophageal cancer	0.00112	0.0032	CcSEcCtD
Paricalcitol—Weight decreased—Capecitabine—esophageal cancer	0.00112	0.00319	CcSEcCtD
Paricalcitol—Pneumonia—Capecitabine—esophageal cancer	0.00111	0.00316	CcSEcCtD
Paricalcitol—Infestation—Capecitabine—esophageal cancer	0.0011	0.00314	CcSEcCtD
Paricalcitol—Infestation NOS—Capecitabine—esophageal cancer	0.0011	0.00314	CcSEcCtD
Paricalcitol—Depression—Capecitabine—esophageal cancer	0.0011	0.00313	CcSEcCtD
Paricalcitol—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00109	0.0031	CcSEcCtD
Paricalcitol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00108	0.00309	CcSEcCtD
Paricalcitol—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00108	0.00198	CbGpPWpGaD
Paricalcitol—Anaemia—Cisplatin—esophageal cancer	0.00108	0.00308	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.00108	0.00197	CbGpPWpGaD
Paricalcitol—Urinary tract infection—Capecitabine—esophageal cancer	0.00107	0.00305	CcSEcCtD
Paricalcitol—Conjunctivitis—Capecitabine—esophageal cancer	0.00107	0.00305	CcSEcCtD
Paricalcitol—Osteoarthritis—Methotrexate—esophageal cancer	0.00107	0.00303	CcSEcCtD
Paricalcitol—Malaise—Cisplatin—esophageal cancer	0.00105	0.003	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.00105	0.00193	CbGpPWpGaD
Paricalcitol—Leukopenia—Cisplatin—esophageal cancer	0.00105	0.00298	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN1A—esophageal cancer	0.00104	0.00191	CbGpPWpGaD
Paricalcitol—Epistaxis—Capecitabine—esophageal cancer	0.00104	0.00296	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00103	0.00189	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00103	0.00189	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP1B1—esophageal cancer	0.000999	0.00183	CbGpPWpGaD
Paricalcitol—Myalgia—Cisplatin—esophageal cancer	0.000995	0.00284	CcSEcCtD
Paricalcitol—Anxiety—Cisplatin—esophageal cancer	0.000992	0.00283	CcSEcCtD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—EP300—esophageal cancer	0.000992	0.00182	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—TGFBR2—esophageal cancer	0.000991	0.00182	CbGpPWpGaD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000988	0.00282	CcSEcCtD
Paricalcitol—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.000987	0.00181	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000985	0.00181	CbGpPWpGaD
Paricalcitol—Hypoaesthesia—Capecitabine—esophageal cancer	0.000985	0.00281	CcSEcCtD
Paricalcitol—Discomfort—Cisplatin—esophageal cancer	0.000983	0.0028	CcSEcCtD
Paricalcitol—Pharyngitis—Capecitabine—esophageal cancer	0.000983	0.0028	CcSEcCtD
Paricalcitol—Urinary tract disorder—Capecitabine—esophageal cancer	0.000978	0.00278	CcSEcCtD
Paricalcitol—UGT1A4—NRF2 pathway—HMOX1—esophageal cancer	0.000977	0.00179	CbGpPWpGaD
Paricalcitol—Oedema peripheral—Capecitabine—esophageal cancer	0.000975	0.00278	CcSEcCtD
Paricalcitol—Connective tissue disorder—Capecitabine—esophageal cancer	0.000973	0.00277	CcSEcCtD
Paricalcitol—Urethral disorder—Capecitabine—esophageal cancer	0.00097	0.00276	CcSEcCtD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000966	0.00177	CbGpPWpGaD
Paricalcitol—Breast disorder—Methotrexate—esophageal cancer	0.000963	0.00274	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—BAX—esophageal cancer	0.000962	0.00176	CbGpPWpGaD
Paricalcitol—Oedema—Cisplatin—esophageal cancer	0.000954	0.00272	CcSEcCtD
Paricalcitol—Infection—Cisplatin—esophageal cancer	0.000948	0.0027	CcSEcCtD
Paricalcitol—UGT1A4—Biological oxidations—CYP19A1—esophageal cancer	0.000939	0.00172	CbGpPWpGaD
Paricalcitol—Nervous system disorder—Cisplatin—esophageal cancer	0.000936	0.00267	CcSEcCtD
Paricalcitol—Skin disorder—Cisplatin—esophageal cancer	0.000927	0.00264	CcSEcCtD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000926	0.0017	CbGpPWpGaD
Paricalcitol—Eye disorder—Capecitabine—esophageal cancer	0.000925	0.00264	CcSEcCtD
Paricalcitol—Hyperhidrosis—Cisplatin—esophageal cancer	0.000922	0.00263	CcSEcCtD
Paricalcitol—Asthma—Methotrexate—esophageal cancer	0.000921	0.00262	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000921	0.00169	CbGpPWpGaD
Paricalcitol—Cardiac disorder—Capecitabine—esophageal cancer	0.000919	0.00262	CcSEcCtD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000917	0.00168	CbGpPWpGaD
Paricalcitol—Anorexia—Cisplatin—esophageal cancer	0.00091	0.00259	CcSEcCtD
Paricalcitol—Pancreatitis—Methotrexate—esophageal cancer	0.000903	0.00257	CcSEcCtD
Paricalcitol—Angiopathy—Capecitabine—esophageal cancer	0.000898	0.00256	CcSEcCtD
Paricalcitol—Immune system disorder—Capecitabine—esophageal cancer	0.000894	0.00255	CcSEcCtD
Paricalcitol—Mediastinal disorder—Capecitabine—esophageal cancer	0.000892	0.00254	CcSEcCtD
Paricalcitol—Hypotension—Cisplatin—esophageal cancer	0.000892	0.00254	CcSEcCtD
Paricalcitol—Chills—Capecitabine—esophageal cancer	0.000888	0.00253	CcSEcCtD
Paricalcitol—Arrhythmia—Capecitabine—esophageal cancer	0.000884	0.00252	CcSEcCtD
Paricalcitol—Abdominal discomfort—Methotrexate—esophageal cancer	0.000883	0.00251	CcSEcCtD
Paricalcitol—Alopecia—Capecitabine—esophageal cancer	0.000875	0.00249	CcSEcCtD
Paricalcitol—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000872	0.0016	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000869	0.00248	CcSEcCtD
Paricalcitol—Mental disorder—Capecitabine—esophageal cancer	0.000867	0.00247	CcSEcCtD
Paricalcitol—Malnutrition—Capecitabine—esophageal cancer	0.000862	0.00245	CcSEcCtD
Paricalcitol—Paraesthesia—Cisplatin—esophageal cancer	0.000857	0.00244	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000856	0.00244	CcSEcCtD
Paricalcitol—Dyspnoea—Cisplatin—esophageal cancer	0.000851	0.00242	CcSEcCtD
Paricalcitol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00085	0.00156	CbGpPWpGaD
Paricalcitol—Erectile dysfunction—Methotrexate—esophageal cancer	0.000848	0.00242	CcSEcCtD
Paricalcitol—Dysgeusia—Capecitabine—esophageal cancer	0.000844	0.0024	CcSEcCtD
Paricalcitol—Back pain—Capecitabine—esophageal cancer	0.000834	0.00237	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—NR1I2—esophageal cancer	0.000833	0.00153	CbGpPWpGaD
Paricalcitol—Decreased appetite—Cisplatin—esophageal cancer	0.000829	0.00236	CcSEcCtD
Paricalcitol—Muscle spasms—Capecitabine—esophageal cancer	0.000829	0.00236	CcSEcCtD
Paricalcitol—Pneumonia—Methotrexate—esophageal cancer	0.000826	0.00235	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000824	0.00235	CcSEcCtD
Paricalcitol—Infestation NOS—Methotrexate—esophageal cancer	0.000821	0.00234	CcSEcCtD
Paricalcitol—Infestation—Methotrexate—esophageal cancer	0.000821	0.00234	CcSEcCtD
Paricalcitol—Depression—Methotrexate—esophageal cancer	0.000819	0.00233	CcSEcCtD
Paricalcitol—Pain—Cisplatin—esophageal cancer	0.000816	0.00232	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000814	0.00149	CbGpPWpGaD
Paricalcitol—Ill-defined disorder—Capecitabine—esophageal cancer	0.0008	0.00228	CcSEcCtD
Paricalcitol—Conjunctivitis—Methotrexate—esophageal cancer	0.000798	0.00227	CcSEcCtD
Paricalcitol—Anaemia—Capecitabine—esophageal cancer	0.000797	0.00227	CcSEcCtD
Paricalcitol—Sweating—Methotrexate—esophageal cancer	0.000787	0.00224	CcSEcCtD
Paricalcitol—Feeling abnormal—Cisplatin—esophageal cancer	0.000786	0.00224	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—MET—esophageal cancer	0.000779	0.00143	CbGpPWpGaD
Paricalcitol—Malaise—Capecitabine—esophageal cancer	0.000777	0.00221	CcSEcCtD
Paricalcitol—Epistaxis—Methotrexate—esophageal cancer	0.000774	0.00221	CcSEcCtD
Paricalcitol—Vertigo—Capecitabine—esophageal cancer	0.000774	0.00221	CcSEcCtD
Paricalcitol—Syncope—Capecitabine—esophageal cancer	0.000773	0.0022	CcSEcCtD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000772	0.00142	CbGpPWpGaD
Paricalcitol—Leukopenia—Capecitabine—esophageal cancer	0.000771	0.0022	CcSEcCtD
Paricalcitol—Palpitations—Capecitabine—esophageal cancer	0.000762	0.00217	CcSEcCtD
Paricalcitol—Loss of consciousness—Capecitabine—esophageal cancer	0.000757	0.00216	CcSEcCtD
Paricalcitol—Body temperature increased—Cisplatin—esophageal cancer	0.000754	0.00215	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.000753	0.00138	CbGpPWpGaD
Paricalcitol—Cough—Capecitabine—esophageal cancer	0.000752	0.00214	CcSEcCtD
Paricalcitol—Hypertension—Capecitabine—esophageal cancer	0.000744	0.00212	CcSEcCtD
Paricalcitol—Arthralgia—Capecitabine—esophageal cancer	0.000734	0.00209	CcSEcCtD
Paricalcitol—Myalgia—Capecitabine—esophageal cancer	0.000734	0.00209	CcSEcCtD
Paricalcitol—Chest pain—Capecitabine—esophageal cancer	0.000734	0.00209	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—esophageal cancer	0.000731	0.00208	CcSEcCtD
Paricalcitol—Anxiety—Capecitabine—esophageal cancer	0.000731	0.00208	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000729	0.00208	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—esophageal cancer	0.000728	0.00207	CcSEcCtD
Paricalcitol—Discomfort—Capecitabine—esophageal cancer	0.000725	0.00206	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—esophageal cancer	0.000722	0.00206	CcSEcCtD
Paricalcitol—Dry mouth—Capecitabine—esophageal cancer	0.000718	0.00204	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000717	0.00132	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.00071	0.0013	CbGpPWpGaD
Paricalcitol—Confusional state—Capecitabine—esophageal cancer	0.000709	0.00202	CcSEcCtD
Paricalcitol—Oedema—Capecitabine—esophageal cancer	0.000703	0.002	CcSEcCtD
Paricalcitol—Hypersensitivity—Cisplatin—esophageal cancer	0.000703	0.002	CcSEcCtD
Paricalcitol—Infection—Capecitabine—esophageal cancer	0.000699	0.00199	CcSEcCtD
Paricalcitol—Shock—Capecitabine—esophageal cancer	0.000692	0.00197	CcSEcCtD
Paricalcitol—Nervous system disorder—Capecitabine—esophageal cancer	0.00069	0.00196	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—esophageal cancer	0.000689	0.00196	CcSEcCtD
Paricalcitol—Asthenia—Cisplatin—esophageal cancer	0.000685	0.00195	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—esophageal cancer	0.000684	0.00195	CcSEcCtD
Paricalcitol—Skin disorder—Capecitabine—esophageal cancer	0.000683	0.00195	CcSEcCtD
Paricalcitol—Hyperhidrosis—Capecitabine—esophageal cancer	0.00068	0.00194	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—CREBBP—esophageal cancer	0.000679	0.00125	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—RB1—esophageal cancer	0.000677	0.00124	CbGpPWpGaD
Paricalcitol—Anorexia—Capecitabine—esophageal cancer	0.00067	0.00191	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—esophageal cancer	0.000669	0.0019	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—esophageal cancer	0.000666	0.0019	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000664	0.00189	CcSEcCtD
Paricalcitol—Chills—Methotrexate—esophageal cancer	0.000661	0.00188	CcSEcCtD
Paricalcitol—Hypotension—Capecitabine—esophageal cancer	0.000657	0.00187	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000656	0.0012	CbGpPWpGaD
Paricalcitol—Diarrhoea—Cisplatin—esophageal cancer	0.000653	0.00186	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000652	0.0012	CbGpPWpGaD
Paricalcitol—Alopecia—Methotrexate—esophageal cancer	0.000651	0.00186	CcSEcCtD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000647	0.00119	CbGpPWpGaD
Paricalcitol—Mental disorder—Methotrexate—esophageal cancer	0.000646	0.00184	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—esophageal cancer	0.000642	0.00183	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000641	0.00183	CcSEcCtD
Paricalcitol—Insomnia—Capecitabine—esophageal cancer	0.000636	0.00181	CcSEcCtD
Paricalcitol—Paraesthesia—Capecitabine—esophageal cancer	0.000632	0.0018	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SLC52A3—esophageal cancer	0.000631	0.00116	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—BLVRB—esophageal cancer	0.000631	0.00116	CbGpPWpGaD
Paricalcitol—Dysgeusia—Methotrexate—esophageal cancer	0.000628	0.00179	CcSEcCtD
Paricalcitol—Dyspnoea—Capecitabine—esophageal cancer	0.000627	0.00179	CcSEcCtD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000625	0.00115	CbGpPWpGaD
Paricalcitol—Back pain—Methotrexate—esophageal cancer	0.000621	0.00177	CcSEcCtD
Paricalcitol—Dyspepsia—Capecitabine—esophageal cancer	0.000619	0.00176	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000615	0.00113	CbGpPWpGaD
Paricalcitol—Decreased appetite—Capecitabine—esophageal cancer	0.000611	0.00174	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000607	0.00173	CcSEcCtD
Paricalcitol—Vomiting—Cisplatin—esophageal cancer	0.000607	0.00173	CcSEcCtD
Paricalcitol—Fatigue—Capecitabine—esophageal cancer	0.000606	0.00173	CcSEcCtD
Paricalcitol—Rash—Cisplatin—esophageal cancer	0.000602	0.00171	CcSEcCtD
Paricalcitol—Constipation—Capecitabine—esophageal cancer	0.000601	0.00171	CcSEcCtD
Paricalcitol—Pain—Capecitabine—esophageal cancer	0.000601	0.00171	CcSEcCtD
Paricalcitol—Dermatitis—Cisplatin—esophageal cancer	0.000601	0.00171	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—esophageal cancer	0.000595	0.0017	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—esophageal cancer	0.000593	0.00169	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—BCL2—esophageal cancer	0.000586	0.00107	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Capecitabine—esophageal cancer	0.00058	0.00165	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—esophageal cancer	0.000579	0.00165	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—esophageal cancer	0.000576	0.00164	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000575	0.00164	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—esophageal cancer	0.000574	0.00164	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000572	0.00105	CbGpPWpGaD
Paricalcitol—Nausea—Cisplatin—esophageal cancer	0.000567	0.00161	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000564	0.00104	CbGpPWpGaD
Paricalcitol—Cough—Methotrexate—esophageal cancer	0.00056	0.00159	CcSEcCtD
Paricalcitol—Urticaria—Capecitabine—esophageal cancer	0.000559	0.00159	CcSEcCtD
Paricalcitol—Body temperature increased—Capecitabine—esophageal cancer	0.000556	0.00158	CcSEcCtD
Paricalcitol—Abdominal pain—Capecitabine—esophageal cancer	0.000556	0.00158	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—esophageal cancer	0.000546	0.00156	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—esophageal cancer	0.000546	0.00156	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—esophageal cancer	0.000546	0.00156	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000542	0.00155	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—esophageal cancer	0.00054	0.00154	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—SLC10A2—esophageal cancer	0.000537	0.000985	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CA1—esophageal cancer	0.000537	0.000985	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000532	0.000975	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SMG6—esophageal cancer	0.000529	0.00097	CbGpPWpGaD
Paricalcitol—Confusional state—Methotrexate—esophageal cancer	0.000528	0.0015	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000523	0.000959	CbGpPWpGaD
Paricalcitol—Infection—Methotrexate—esophageal cancer	0.00052	0.00148	CcSEcCtD
Paricalcitol—Hypersensitivity—Capecitabine—esophageal cancer	0.000518	0.00148	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—esophageal cancer	0.000513	0.00146	CcSEcCtD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000513	0.00094	CbGpPWpGaD
Paricalcitol—Skin disorder—Methotrexate—esophageal cancer	0.000509	0.00145	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000506	0.00144	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—BLVRB—esophageal cancer	0.000505	0.000926	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SLC52A3—esophageal cancer	0.000505	0.000926	CbGpPWpGaD
Paricalcitol—Asthenia—Capecitabine—esophageal cancer	0.000505	0.00144	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—esophageal cancer	0.000499	0.00142	CcSEcCtD
Paricalcitol—Pruritus—Capecitabine—esophageal cancer	0.000498	0.00142	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CA2—esophageal cancer	0.000491	0.0009	CbGpPWpGaD
Paricalcitol—Hypotension—Methotrexate—esophageal cancer	0.000489	0.00139	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000488	0.000896	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CDKN1A—esophageal cancer	0.000486	0.000892	CbGpPWpGaD
Paricalcitol—Diarrhoea—Capecitabine—esophageal cancer	0.000481	0.00137	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.00048	0.00088	CbGpPWpGaD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000477	0.00136	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—esophageal cancer	0.000474	0.00135	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—esophageal cancer	0.00047	0.00134	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000469	0.00086	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000467	0.000857	CbGpPWpGaD
Paricalcitol—Dyspnoea—Methotrexate—esophageal cancer	0.000467	0.00133	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000466	0.000854	CbGpPWpGaD
Paricalcitol—Somnolence—Methotrexate—esophageal cancer	0.000465	0.00133	CcSEcCtD
Paricalcitol—Dizziness—Capecitabine—esophageal cancer	0.000465	0.00132	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—EP300—esophageal cancer	0.000463	0.000849	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000461	0.000846	CbGpPWpGaD
Paricalcitol—Dyspepsia—Methotrexate—esophageal cancer	0.000461	0.00131	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—PLCE1—esophageal cancer	0.000456	0.000837	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ADH7—esophageal cancer	0.000456	0.000837	CbGpPWpGaD
Paricalcitol—Decreased appetite—Methotrexate—esophageal cancer	0.000455	0.0013	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000452	0.00129	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—esophageal cancer	0.000451	0.00129	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000451	0.000827	CbGpPWpGaD
Paricalcitol—Pain—Methotrexate—esophageal cancer	0.000448	0.00128	CcSEcCtD
Paricalcitol—Vomiting—Capecitabine—esophageal cancer	0.000447	0.00127	CcSEcCtD
Paricalcitol—Rash—Capecitabine—esophageal cancer	0.000443	0.00126	CcSEcCtD
Paricalcitol—Dermatitis—Capecitabine—esophageal cancer	0.000443	0.00126	CcSEcCtD
Paricalcitol—Headache—Capecitabine—esophageal cancer	0.000441	0.00126	CcSEcCtD
Paricalcitol—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000438	0.000803	CbGpPWpGaD
Paricalcitol—Feeling abnormal—Methotrexate—esophageal cancer	0.000431	0.00123	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—SLC10A2—esophageal cancer	0.000429	0.000787	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CA1—esophageal cancer	0.000429	0.000787	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000428	0.00122	CcSEcCtD
Paricalcitol—Nausea—Capecitabine—esophageal cancer	0.000418	0.00119	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—esophageal cancer	0.000416	0.00118	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—esophageal cancer	0.000414	0.00118	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—esophageal cancer	0.000414	0.00118	CcSEcCtD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000403	0.000739	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NR1I2—esophageal cancer	0.000401	0.000735	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ADH1B—esophageal cancer	0.0004	0.000734	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—EGFR—esophageal cancer	0.000394	0.000723	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—SMAD4—esophageal cancer	0.000394	0.000723	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CA2—esophageal cancer	0.000392	0.00072	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Methotrexate—esophageal cancer	0.000386	0.0011	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—TYMP—esophageal cancer	0.000382	0.000702	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000379	0.000695	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000377	0.000691	CbGpPWpGaD
Paricalcitol—Asthenia—Methotrexate—esophageal cancer	0.000376	0.00107	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—CYP26A1—esophageal cancer	0.000372	0.000682	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000372	0.000682	CbGpPWpGaD
Paricalcitol—Pruritus—Methotrexate—esophageal cancer	0.00037	0.00106	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ADH7—esophageal cancer	0.000365	0.000669	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PLCE1—esophageal cancer	0.000365	0.000669	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALOX15—esophageal cancer	0.000363	0.000665	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000359	0.000659	CbGpPWpGaD
Paricalcitol—Diarrhoea—Methotrexate—esophageal cancer	0.000358	0.00102	CcSEcCtD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000354	0.000649	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000349	0.000641	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000346	0.000635	CbGpPWpGaD
Paricalcitol—Dizziness—Methotrexate—esophageal cancer	0.000346	0.000986	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GSTO1—esophageal cancer	0.000346	0.000634	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—TPI1—esophageal cancer	0.000346	0.000634	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—HIST1H2BM—esophageal cancer	0.000344	0.000631	CbGpPWpGaD
Paricalcitol—Vomiting—Methotrexate—esophageal cancer	0.000333	0.000948	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ALDOB—esophageal cancer	0.000332	0.000608	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TP53—esophageal cancer	0.000331	0.000607	CbGpPWpGaD
Paricalcitol—Rash—Methotrexate—esophageal cancer	0.00033	0.00094	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—esophageal cancer	0.00033	0.000939	CcSEcCtD
Paricalcitol—Headache—Methotrexate—esophageal cancer	0.000328	0.000934	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ADH1B—esophageal cancer	0.00032	0.000587	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GAPDH—esophageal cancer	0.000319	0.000586	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CRABP1—esophageal cancer	0.000316	0.00058	CbGpPWpGaD
Paricalcitol—Nausea—Methotrexate—esophageal cancer	0.000311	0.000886	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—TYMP—esophageal cancer	0.000306	0.000561	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000305	0.00056	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000304	0.000557	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GNG7—esophageal cancer	0.000301	0.000552	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP26A1—esophageal cancer	0.000297	0.000546	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.00029	0.000533	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALOX15—esophageal cancer	0.00029	0.000532	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000287	0.000526	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000282	0.000518	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ALDH2—esophageal cancer	0.000282	0.000517	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000278	0.000511	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTO1—esophageal cancer	0.000277	0.000507	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—TPI1—esophageal cancer	0.000277	0.000507	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTT1—esophageal cancer	0.000268	0.000492	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PSME2—esophageal cancer	0.000267	0.00049	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PSME1—esophageal cancer	0.000267	0.00049	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP2A6—esophageal cancer	0.000265	0.000486	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALDOB—esophageal cancer	0.000265	0.000486	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000264	0.000484	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CREBBP—esophageal cancer	0.000263	0.000483	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000262	0.000481	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000259	0.000475	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GAPDH—esophageal cancer	0.000255	0.000468	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CRABP1—esophageal cancer	0.000253	0.000464	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NOTCH3—esophageal cancer	0.000252	0.000462	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS1—esophageal cancer	0.000251	0.000461	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ENO1—esophageal cancer	0.000251	0.000461	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PSME1—esophageal cancer	0.000248	0.000454	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PSME2—esophageal cancer	0.000248	0.000454	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GNG7—esophageal cancer	0.000241	0.000441	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NOTCH2—esophageal cancer	0.000226	0.000414	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ALDH2—esophageal cancer	0.000225	0.000413	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000216	0.000397	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTT1—esophageal cancer	0.000214	0.000393	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000214	0.000392	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP1B1—esophageal cancer	0.000214	0.000392	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP2A6—esophageal cancer	0.000212	0.000389	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000204	0.000373	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000201	0.000369	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP19A1—esophageal cancer	0.000201	0.000369	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS1—esophageal cancer	0.000201	0.000369	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ENO1—esophageal cancer	0.000201	0.000369	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PSME1—esophageal cancer	0.000198	0.000363	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PSME2—esophageal cancer	0.000198	0.000363	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000191	0.00035	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SMAD4—esophageal cancer	0.00019	0.000348	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—HMOX1—esophageal cancer	0.000183	0.000336	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.00018	0.00033	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ABCB1—esophageal cancer	0.000176	0.000323	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP1B1—esophageal cancer	0.000171	0.000313	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000162	0.000297	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP19A1—esophageal cancer	0.000161	0.000295	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00016	0.000293	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—esophageal cancer	0.000156	0.000287	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000152	0.00028	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00015	0.000276	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—HMOX1—esophageal cancer	0.000147	0.000269	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ABCB1—esophageal cancer	0.000141	0.000258	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—NOTCH1—esophageal cancer	0.00014	0.000256	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000133	0.000244	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—CREBBP—esophageal cancer	0.000127	0.000232	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CREBBP—esophageal cancer	0.000118	0.000216	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NOS3—esophageal cancer	0.000105	0.000193	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—esophageal cancer	9.63e-05	0.000177	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CREBBP—esophageal cancer	9.4e-05	0.000172	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NOS3—esophageal cancer	8.42e-05	0.000154	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—BLVRB—esophageal cancer	8.19e-05	0.00015	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC52A3—esophageal cancer	8.19e-05	0.00015	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—EP300—esophageal cancer	8.01e-05	0.000147	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—esophageal cancer	7.7e-05	0.000141	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—esophageal cancer	7.52e-05	0.000138	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC10A2—esophageal cancer	6.97e-05	0.000128	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CA1—esophageal cancer	6.97e-05	0.000128	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—EP300—esophageal cancer	6.4e-05	0.000117	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CA2—esophageal cancer	6.37e-05	0.000117	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PIK3CA—esophageal cancer	5.93e-05	0.000109	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ADH7—esophageal cancer	5.92e-05	0.000109	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PLCE1—esophageal cancer	5.92e-05	0.000109	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ADH1B—esophageal cancer	5.19e-05	9.53e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TYMP—esophageal cancer	4.96e-05	9.1e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	4.83e-05	8.86e-05	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PIK3CA—esophageal cancer	4.74e-05	8.69e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALOX15—esophageal cancer	4.71e-05	8.63e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTO1—esophageal cancer	4.49e-05	8.23e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TPI1—esophageal cancer	4.49e-05	8.23e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALDOB—esophageal cancer	4.3e-05	7.89e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GAPDH—esophageal cancer	4.14e-05	7.6e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CRABP1—esophageal cancer	4.11e-05	7.53e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GNG7—esophageal cancer	3.91e-05	7.16e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ALDH2—esophageal cancer	3.66e-05	6.71e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTT1—esophageal cancer	3.48e-05	6.38e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	3.44e-05	6.31e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS1—esophageal cancer	3.26e-05	5.98e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ENO1—esophageal cancer	3.26e-05	5.98e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSME2—esophageal cancer	3.21e-05	5.89e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PSME1—esophageal cancer	3.21e-05	5.89e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.77e-05	5.09e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.61e-05	4.78e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HMOX1—esophageal cancer	2.38e-05	4.36e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ABCB1—esophageal cancer	2.28e-05	4.19e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.53e-05	2.8e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NOS3—esophageal cancer	1.37e-05	2.51e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.25e-05	2.29e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—EP300—esophageal cancer	1.04e-05	1.91e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	7.69e-06	1.41e-05	CbGpPWpGaD
